

ASX Release

SUDA Update

PERTH, AUSTRALIA – 18th January 2021: SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, advises the following changes after a review of operations.

SUDA continues to focus on the projects we believe are most likely to create value for SUDA and for Shareholders. A strategic review identified areas where SUDA can increase efficiency, balancing the resources required for ongoing product development. This is in line with the Company's goal of managing expenditure and maximising available resources.

As a result of the strategic review, the role of Chief Technical Officer will be assumed by SUDA's General Manager, Tony Macintyre, and the CEO & MD, Dr Michael Baker.

Dr Baker commented: "We are committed to ensuring that SUDA has the most efficient team in place to deliver on the projects we believe are likely to return value to Shareholders. In addition, we are continuing to evaluate a number of technologies for potential acquisition that align with our focus areas, oncology and the central nervous system."

For and on behalf of the Board and for further information please contact:

Dr Michael Baker

Chief Executive Officer & Managing Director

SUDA Pharmaceuticals Ltd

Tel +61 (0) 403 468 187

mbaker@sudapharma.com

NOTES TO EDITORS:

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e. cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem tartrate for the treatment of short-term insomnia. ZolpiMist is approved by the TGA and is marketed in the USA. SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays for the treatment of migraine headache, motion sickness, drug resistant epilepsy and certain cancers.

For more information, visit www.sudapharma.com